Abstract
Rotaviruses are the commonest cause of severe watery diarrheal disease in infants and young children, causing an estimated 352,000–592,000 deaths per year, mostly in developing countries. In 1999, the first rotavirus vaccine to be licensed in the USA (RotaShield®) was withdrawn . However, before use of the vaccine was suspended, several economic evaluations were performed. Recently, two rotavirus vaccines, Rotarix® and RotaTeq®, have completed Phase III clinical trials. The first economic evaluations of these new rotavirus vaccines are now appearing. The purpose of this paper is to review the existing cost–effectiveness evidence-base, and to provide methodologic suggestions for future analyses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Expert Review of Pharmacoeconomics & Outcomes Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
